BlueOcean Ventures
VC Fund
Plan-les-ouates, Switzerland
BlueOcean Ventures is a VC fund in Plan-les-ouates focused on Health Care and Medical. BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BlueOcean Ventures invests in
Stages BlueOcean Ventures invests in
Countries BlueOcean Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$3.1M
- Series A
- $2.3M–$20M
- Series B
- $4M–$16M
Investment Focus
Industry
- Health Care 11 (65%)
- Medical 8 (47%)
- Personal Health 7 (41%)
- Biotechnology 5 (29%)
- Medical Device 5 (29%)
Stage
- Seed 5 (29%)
- Series A 5 (29%)
- Series B 3 (18%)
- Venture - Series Unknown 3 (18%)
- Funding Round 1 (6%)
Country
- Switzerland 11 (65%)
- India 2 (12%)
- France 1 (6%)
- Bulgaria 1 (6%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Thomas Zehnder
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RockFlow is an artificial intelligence fintech company headquartered in Singapore, with offices in 5 countries and regions worldwide. As a next-generation AI-native trading platform, RockFlow offers users a personalized AI investment assistant. It delivers real-time trading insights and position management services tailored to individual targetreturns, risk preferences, and other criteria.The team has a background in cross-border innovation and rich practical and continuous entrepreneurial experience in artificial intelligence, financial engineering, and technology industries. The core members of the company come from top technology companies and financial institutions such as Facebook, Baidu, ByteDance, Huawei, Intel, Vanguard Group, Goldman Sachs, CITIC Securities, and ORC. Many members graduated from top universities in the world, such as MIT, Imperial College London, University of California, Berkeley, and Columbia University.As an AI investment platform, RockFlow is committed to achieving financial equality through AI, allowing everyone to easily experience the joy of simple investment. The product has 9 languages and users are located in more than 30 countries and regions around the world.Since its inception, RockFlow has received $10 million Angel Round Financing led by BlueRun Ventures. Since its inception, RockFlow has been a major promoter of investment innovation, trusted by top global financial institutions and Silicon Valley dollar funds. Current partners include NASDAQ, HKEx, Refinitiv, NYSE, ICE, Interactive Brokers, and HSBC. | Venture - Series Unknown / Nov 20, 2025 | ||
| UGX.ai is a manufacturing firm with real time traceability and AI based quality inspection for complete operational visibly. | $1M / Seed / Sep 18, 2025 | ||
| nPloy is the job platform that transforms the way employers and candidates find the perfect match.We know that job hunting can be an unnecessarily complicated and mundane process. On the other side, talent search has become excessively expensive and consuming in terms of time and energy. nPloy stands against all of this.employ's mission isto provide candidates with the job hunting experience that works and to save organizations from the hassle linked to a talent search. Candidates prefer nPloy for its easy-to-use interface and unique features, such as 100% anonymity, and guaranteed feedback from employers. Companies trust nPloy for its diverse talent pool, and modern approach towards exploring and reaching talents.With more than 160 partners & 35,000 users (and growing), we keep improving your talent and job searching experience. | $2.2M / Seed / Nov 23, 2023 | ||
| Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib. | $2.5M / Seed / Jun 08, 2020 | ||
| Cyanoguard AG is a chemical technology company specialised in the development of novel toxin detection methods to improve environmental monitoring, food safety and health care in remote settings and locations. Its innovative technology enables fast and safe cyanide detection in food, waste water and other samples. Its method is selective andrequires no special training and/or equipment.Equipped with the latest research, and with over six years of close collaboration with leading industry partners, the company is dedicated to resolve today's cyanide issues, offering fast and safe toxin detection in any setting at any time. | $3.1M / Seed / Apr 14, 2020 | ||
| 99RetailStreet is a common commerce platform on cloud targeted at the large unorganized retail segment comprising of “Kiranas/ Kades”, Pharmacies and other consumer facing retail businesses in developing markets. It is built to enhance the retailers’ business through faster Sales Growth, better Financial Capabilities and improved Efficiencyacross the value chain. | Seed / Jun 09, 2017 | ||
| Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days. | $9.7M / Series A / Nov 15, 2016 | ||
| Rheon Medical manufactures eyeWatch, a drainage device for the treatment of glaucoma. It also offers control unit, an instrument that measures and adjusts the eyeWatch's functional position. Rheon Medical began operation in 2010. Its headquarters is in Lausanne in Switzerland. | Venture - Series Unknown / Oct 20, 2016 | ||
| Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from: | $4M / Series B / Oct 14, 2014 | ||
| Augurix was born out of the real-life experiences of living with Celiac Disease. In 2004, Cecile – a pediatrician with an MD and PhD in immunology – noticed her 18-month old son Simon exhibiting symptoms of the disease. As a professional and having been diagnosed herself some thirty years earlier, she was able to spot the early warning signs. ButCecile was also acutely aware that despite affecting almost 1 in 100 people, Celiac Disease was difficult to diagnose.Cecile and her husband Thierry became determined to find a way to change this, giving parents and their children the best chance of an accurate diagnosis and the ability to live their lives free of the often debilitating symptoms. Using Swiss medical expertise Augurix was founded in 2007, with a mission to provide primary care doctors with an easy-to-use, affordable tool, to lower the hurdle of diagnostics.In 2010 Simtomax® was launched – a rapid screening test for the early determination of Celiac Disease at the point-of-care – finally bringing Cecile’s vision to life. Today, Augurix is pursuing its vision by enlarging its diagnostics offer to other gastrointestinal diseases. | $3.3M / Venture - Series Unknown / Jan 27, 2014 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BlueOcean Ventures invest in?
BlueOcean Ventures invests primarily in Health Care, Medical and Personal Health startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does BlueOcean Ventures invest in?
BlueOcean Ventures typically joins rounds of $1M–$3.1M at Seed, $2.3M–$20M at Series A and $4M–$16M at Series B. These are whole funding-round sizes, not BlueOcean Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds BlueOcean Ventures took part in.
How do I contact BlueOcean Ventures?
Public channels for BlueOcean Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BlueOcean Ventures?
The team at BlueOcean Ventures includes Thomas Zehnder (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
